<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114720</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-015</org_study_id>
    <nct_id>NCT05114720</nct_id>
  </id_info>
  <brief_title>Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer</brief_title>
  <official_title>A Multicenter, Placebo-Controlled, Phase III Trial of Standard Adjuvant Chemotherapy Plus Moxifloxacin in Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare disease-free survival (DFS) of patients&#xD;
      with operable breast cancer randomised to treatment with standard adjuvant chemotherapy plus&#xD;
      moxifloxacin or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomised, double-blind, placebo-controlled, phase 3 clinical trial.&#xD;
      The main purposes of this study are to examine the efficacy and safety of standard adjuvant&#xD;
      chemotherapy plus moxifloxacin or placebo as care for patients with operable breast cancer.&#xD;
      This study is designed to recruit up to 520 subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>10 years</time_frame>
    <description>The interval from the date of randomization until the first date of recurrence local, regional or distant, second primary tumor or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>10 years</time_frame>
    <description>The interval from the date of randomization until the first date on death due to any cause, or the last follow-up time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant disease-free survival (DDFS)</measure>
    <time_frame>10 years</time_frame>
    <description>The interval from the date of randomization until the first date on distant metastasis, death due to any cause, or second primary invasive breast cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>standard adjuvant chemotherapy plus moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard adjuvant chemotherapy (Taxanes combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by taxanes) plus antibiotic (moxifloxacin)&#xD;
Other Name: docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, combined with cyclophosphamide 600 mg/m^2, IV, days 1, followed by docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard adjuvant chemotherapy plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus placebo&#xD;
Other Name: docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, combined with cyclophosphamide 600 mg/m^2, IV, days 1, followed by docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard adjuvant chemotherapy plus moxifloxacin</intervention_name>
    <description>docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m^2, IV, days 1, cycled every 21 days; plus Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days</description>
    <arm_group_label>standard adjuvant chemotherapy plus moxifloxacin</arm_group_label>
    <other_name>Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus antibiotic (moxifloxacin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard adjuvant chemotherapy plus placebo</intervention_name>
    <description>docetaxel 75mg/m^2, or nab-paclitaxel 260mg/m^2, IV, days 1 cyclophosphamide 1000 mg/m^2, IV, days 1, cycled every 21 days; or doxorubicin 60mg/m^2, IV, days 1, cycled every 21 days cyclophosphamide 600 mg/m^2, IV, days 1, cycled every 21 days docetaxel 100 mg/m^2, IV, days 1, cycled every 21 days; plus Placebo 0.4 PO once daily days 1-5; cycled every 21 days</description>
    <arm_group_label>standard adjuvant chemotherapy plus placebo</arm_group_label>
    <other_name>Standard adjuvant chemotherapy (Docetaxel combined with cyclophosphamide or doxorubicin combined with cyclophosphamide followed by docetaxel) plus placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have provided written and signed informed consent;&#xD;
&#xD;
          2. Histologically confirmed invasive ductal carcinoma;&#xD;
&#xD;
          3. Planned to received (neo)/adjuvant chemotherapy;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) score of 0 to 1;&#xD;
&#xD;
          5. Normal blood routine, liver and kidney functions within 1 week before enrollment in&#xD;
             this study;&#xD;
&#xD;
          6. Women of childbearing age have a negative serum or urinary pregnancy tests prior to&#xD;
             enrollment in this study; Pre-menopause women are contracepted with medically&#xD;
             acceptable methods during the study period.&#xD;
&#xD;
          7. Compliance with the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breast feeding;&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) score â‰¥ 2;&#xD;
&#xD;
          3. Hypersensitivity to moxifloxacin or quinolones compounds;&#xD;
&#xD;
          4. Concomitant with other antitumor therapies or participating in other clinical trials;&#xD;
&#xD;
          5. Have a history of heart disease, such as arrhythmia, conduction block, S-T segment&#xD;
             elevation, ischemic heart disease, or congenital heart disease;&#xD;
&#xD;
          6. Severe uncontrolled co-infection, or severe metabolic disorders;&#xD;
&#xD;
          7. A clear past history of neurological or psychiatric disorders, including epilepsy or&#xD;
             dementia;&#xD;
&#xD;
          8. Poor compliance, unwillingness or inability to follow protocol to continue the study;&#xD;
&#xD;
          9. Any circumstances in which the investigator deemed the subject unsuitable for&#xD;
             enrollment in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhongyu Yuan, Professor</last_name>
    <phone>+862087343794</phone>
    <email>yuanzhy@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuanyi Zhong, MD</last_name>
    <phone>862087342496</phone>
    <email>zhongyy@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-Yu Yuan, M.D.</last_name>
      <phone>86-20-87343794</phone>
      <email>yuanzhy@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 14, 2021</last_update_submitted>
  <last_update_submitted_qc>November 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>moxifloxacin</keyword>
  <keyword>operable breast cancer</keyword>
  <keyword>adjuvant treatment</keyword>
  <keyword>disease-free survival</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We decided to not share our individual participant data (IPD) to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

